A bayesian reanalysis of the phase III aducanumab (ADU) trial

07/08/2021

∙

by   Tommaso Costa, et al.

∙

0

∙

share

In this article we have conducted a reanalysis of the phase III aducanumab (ADU) summary statistics announced by Biogen, in particular the result of the Clinical Dementia Rating-Sum of Boxes (CDR-SB). The results showed that the evidence on the efficacy of the drug is very low and a more clearer view of the results of clinical trials are presented in the Bayesian framework that can be useful for future development and research in the field.